Vaccitech plc (VACC) News
Filter VACC News Items
VACC News Results
|Loading, please wait...|
Latest VACC News From Around the Web
Below are the latest news stories about Vaccitech plc that investors may wish to consider to help them evaluate VACC as an investment opportunity.
(Bloomberg) -- The co-founder of Google’s high-profile DeepMind artificial intelligence lab has left Alphabet Inc. to join venture capital firm Greylock Partners, following a turbulent tenure.Most Read from BloombergStock Rebound Fails and Futures Plunge on Earnings: Markets WrapA Nor’easter Approaching New York Risks Becoming a Bomb CycloneMark Zuckerberg’s Stablecoin Ambitions Unravel With Diem Sale TalksNvidia Quietly Prepares to Abandon $40 Billion Arm BidTech Giants Rally Amid Bullish Outlo
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Vaccitech Plc (VACC – Research Report), with a price target of $23.00. The company's shares closed last Tuesday at $9.98. According to TipRanks.com, Chen is a 5-star analyst with an average return of 24.0% and a 37.4% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics. Currently, the analyst consensus on Vaccitech Plc is a Moderate Buy with an average price target of $23.00.
Cancer Research UK, Vaccitech (VACC) and the Ludwig Institute for Cancer Research said the first patient was dosed in a phase 1/2a trial called MAGE trial evaluating
OXFORD, United Kingdom, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Cancer Research UK, Vaccitech plc (Nasdaq: VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient dosed in the MAGE trial, which is testing a novel immunotherapeutic, VTP-600, in patients with the most common type of lung cancer. The phase I/IIa trial is expected to enroll approximately 86 people who have been newly diagnosed with non-small cell lung cancer (NSCLC) and will be testing the safety and
Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape
OXFORD, United Kingdom, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc ("Vaccitech"), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced it will host a virtual Key Opinion Leader ("KOL") event on VTP-300, in development as a key component of a functional cure therapy for chronic hepatitis B (CHB) infection, and the broader CHB therapeutics landscape. The event will be webcast live on January 25 th at 8:30 a.m. EST. Featured speakers: Dr. Kaushik Agarwal, consultant hepatologist and transplant physician at the Institute of Liver Studies at King''s College Hospital, Viral Hepatitis Service lead, and Director of the NIHR South London Clinical Research Network. Dr. Henry L. Y. Chan, head of the Divis...
Wall Street Analysts Believe Vaccitech PLC Sponsored ADR (VACC) Could Rally 113%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 112.8% in Vaccitech PLC Sponsored ADR (VACC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Vaccitech plc (NASDAQ:VACC) Director Robin Wright purchased 10,000 shares of the business’s stock in a transaction on Wednesday, December 22nd. The stock was purchased at an average cost of $9.97 per share, with a total value of $99,700.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. […]
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Allogene Therapeutics (ALLO) and Vaccitech Plc (VACC)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Inovio Pharmaceuticals (INO – Research Report), Allogene Therapeutics (ALLO – Research Report) and Vaccitech Plc (VACC – Research Report). Inovio Pharmaceuticals (INO) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals. The company's shares closed last Tuesday at $5.91, close to its 52-week low of $5.75. According to TipRanks.
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ:
No summary available.